
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
Krista Qualmann, MS, CGC, genetic counselor at the Memorial Hermann Mischer Neuroscience Institute at the Texas Medical Center and UTHealth, discusses the implications that genetic testing results can have on treatment options for patients with brain cancer.
For some hereditary syndromes, certain treatments might be more or less effective. As an example, patients with low-grade gliomas and certain syndromes should avoid ionizing radiation, Qualmann says. Additionally, testing is important to keep in mind when considering screening for other cancers. Many syndromes, including Li-Fraumeni syndrome, can put a patient at higher risk for other cancer types.
<<<





